FDA has cleared the first decellularized replacement heart valve from donated human tissue. Manufactured by CryoLife Inc. (Kennesaw, GA), the allograft uses human tissue from a cadaver and removes the tissue's cells, along with cellular debris. When human tissue is removed from a cadaver, it's inspected and decontaminated. The extra decellularization step taken by CryoLife helps to prevent rejection from the body, because the process leaves a scaffold of connective tissue that works like a human heart valve. The CryoValve SynerGraft Pulmonary Valve and Valved-Conduit Allograft has been cleared for use in patients who need their pulmonary valve replaced as a result of disease, malformation, or the malfunction of their pulmonary valve. The graft could potentially be helpful for children, because allograft heart valves avoid the need for taking blood-thinning drugs for long periods of time.